Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis
- 1 July 2021
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 134 (7) , e415-e419
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
- Pfizer
- Janssen Pharmaceutica
This publication has 16 references indexed in Scilit:
- A Feasible, Simple, Cost-Saving Program to End Cardiovascular Disease in the United StatesThe American Journal of Medicine, 2019
- Effects of Icosapent Ethyl on Total Ischemic EventsJACC, 2019
- The Economic Burden of Hypertriglyceridemia Among US Adults With Diabetes or Atherosclerotic Cardiovascular Disease on Statin Therapy*Journal of Clinical Lipidology, 2019
- Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT TrialCirculation, 2019
- Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaNew England Journal of Medicine, 2019
- A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness AnalysesValue in Health, 2018
- The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care ValueValue in Health, 2018
- Absolute risks rather than incidence rates should be used to estimate the number needed to treat from time-to-event dataJournal of Clinical Epidemiology, 2013
- Number needed to treat is incorrect without proper time-related considerationsJournal of Clinical Epidemiology, 2012
- Confidence intervals for the number needed to treatBMJ, 1998